

David J Nutt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3010967/publications.pdf>

Version: 2024-02-01

579
papers

42,901
citations

1994

101
h-index

3830

178
g-index

615
all docs

615
docs citations

615
times ranked

29422
citing authors

#	ARTICLE	IF	CITATIONS
1	A Multicriteria Decision Analysis Comparing Pharmacotherapy for Chronic Neuropathic Pain, Including Cannabinoids and Cannabis-Based Medical Products. Cannabis and Cannabinoid Research, 2022, 7, 482-500.	2.9	23
2	Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine?. Journal of Psychopharmacology, 2022, 36, 6-11.	4.0	28
3	Developing a real-world evidence base for prescribed cannabis in the United Kingdom: preliminary findings from Project Twenty21. Psychopharmacology, 2022, 239, 1147-1155.	3.1	25
4	Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey. Psychopharmacology, 2022, 239, 1425-1440.	3.1	13
5	Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. Journal of Psychopharmacology, 2022, 36, 258-272.	4.0	103
6	Relationship between astrocyte reactivity, using novel 11C-BU99008 PET, and glucose metabolism, grey matter volume and amyloid load in cognitively impaired individuals. Molecular Psychiatry, 2022, 27, 2019-2029.	7.9	19
7	A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. Molecular Psychiatry, 2022, 27, 1286-1299.	7.9	68
8	Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review. BJPsych Open, 2022, 8, e19.	0.7	45
9	Debunking the myth of “Blue Mondays”: No evidence of affect drop after taking clinical MDMA. Journal of Psychopharmacology, 2022, 36, 360-367.	4.0	8
10	Increased global integration in the brain after psilocybin therapy for depression. Nature Medicine, 2022, 28, 844-851.	30.7	175
11	Effects of classic psychedelic drugs on turbulent signatures in brain dynamics. Network Neuroscience, 2022, 6, 1104-1124.	2.6	10
12	Regulating the oxides of nitrogen “popping the myths. Drug Science, Policy and Law, 2022, 8, 205032452210852.	1.3	1
13	Individual and combined effects of cannabidiol and Δ^9 -tetrahydrocannabinol on striato-cortical connectivity in the human brain. Journal of Psychopharmacology, 2022, 36, 732-744.	4.0	10
14	Acute effects of cannabis on speech illusions and psychotic-like symptoms: two studies testing the moderating effects of cannabidiol and adolescence. Psychological Medicine, 2021, 51, 2134-2142.	4.5	13
15	GABA-A receptor differences in schizophrenia: a positron emission tomography study using [11C]Ro154513. Molecular Psychiatry, 2021, 26, 2616-2625.	7.9	53
16	Acute effects of MDMA on trust, cooperative behaviour and empathy: A double-blind, placebo-controlled experiment. Journal of Psychopharmacology, 2021, 35, 547-555.	4.0	15
17	Imidazoline ligand BU224 reverses cognitive deficits, reduces microgliosis and enhances synaptic connectivity in a mouse model of Alzheimer's disease. British Journal of Pharmacology, 2021, 178, 654-671.	5.4	11
18	The Current Status of Psychedelics in Psychiatry. JAMA Psychiatry, 2021, 78, 121.	11.0	116

#	ARTICLE	IF	CITATIONS
19	Chronic alcohol exposure differentially modulates structural and functional properties of amygdala: A cross-sectional study. <i>Addiction Biology</i> , 2021, 26, e12980.	2.6	2
20	The entropic tongue: Disorganization of natural language under LSD. <i>Consciousness and Cognition</i> , 2021, 87, 103070.	1.5	20
21	Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. <i>Acta Psychiatrica Scandinavica</i> , 2021, 143, 101-118.	4.5	137
22	Medical cannabis and epilepsy in the UK – A qualitative analysis of the carers' perspective: 'We're asking for quality of life for our children'. <i>Drug Science, Policy and Law</i> , 2021, 7, 205032452110349.	1.3	5
23	First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder. <i>Journal of Psychopharmacology</i> , 2021, 35, 375-383.	4.0	66
24	Sex differences in depressive symptoms and tolerability after treatment with selective serotonin reuptake inhibitor antidepressants: Secondary analyses of the GENPOD trial. <i>Journal of Psychopharmacology</i> , 2021, 35, 919-927.	4.0	4
25	Self-blinding citizen science to explore psychedelic microdosing. <i>ELife</i> , 2021, 10, .	6.0	94
26	A Risky Business? Comparing the Harms of Alcohol and Other Recreational Drugs. <i>Significance</i> , 2021, 18, 40-42.	0.4	1
27	Functional evaluation of NK1 antagonism on cue reactivity in opiate dependence; An fMRI study. <i>Drug and Alcohol Dependence</i> , 2021, 221, 108564.	3.2	2
28	Some Contributions on How to Formulate Drug Policies and Provide Evidence-Based Regulation. <i>American Journal of Bioethics</i> , 2021, 21, 28-31.	0.9	1
29	Trial of Psilocybin versus Escitalopram for Depression. <i>New England Journal of Medicine</i> , 2021, 384, 1402-1411.	27.0	643
30	Putting the MD back into MDMA. <i>Nature Medicine</i> , 2021, 27, 950-951.	30.7	1
31	A multi criteria decision analysis (MCDA) for evaluating and appraising government policy responses to non medical heroin use. <i>International Journal of Drug Policy</i> , 2021, 91, 103180.	3.3	8
32	Current controversies in medical cannabis: Recent developments in human clinical applications and potential therapeutics. <i>Neuropharmacology</i> , 2021, 191, 108586.	4.1	42
33	More than just smoke: Psychopharmacology of cannabinoids. <i>Journal of Psychopharmacology</i> , 2021, 35, 771-772.	4.0	1
34	Astrocyte reactivity with late-onset cognitive impairment assessed in vivo using ¹¹ C-BU99008 PET and its relationship with amyloid load. <i>Molecular Psychiatry</i> , 2021, 26, 5848-5855.	7.9	43
35	Acute acetate administration increases endogenous opioid levels in the human brain: A [¹¹ C]carfentanil molecular imaging study. <i>Journal of Psychopharmacology</i> , 2021, 35, 606-610.	4.0	3
36	Study Protocol for 'Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study'. <i>Frontiers in Psychiatry</i> , 2021, 12, 735523.	2.6	33

#	ARTICLE	IF	CITATIONS
37	Alcohol and the Brain. <i>Nutrients</i> , 2021, 13, 3938.	4.1	28
38	Medical cannabis for severe treatment resistant epilepsy in children: a case-series of 10 patients. <i>BMJ Paediatrics Open</i> , 2021, 5, e001234.	1.4	5
39	Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression. <i>Frontiers in Pharmacology</i> , 2021, 12, 788155.	3.5	77
40	Blunted endogenous opioid release following an oral dexamphetamine challenge in abstinent alcohol-dependent individuals. <i>Molecular Psychiatry</i> , 2020, 25, 1749-1758.	7.9	23
41	New psychoactive substances: Pharmacology influencing UK practice, policy and the law. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 445-451.	2.4	11
42	The development and validation of a human screening model of tobacco abstinence. <i>Drug and Alcohol Dependence</i> , 2020, 206, 107720.	3.2	1
43	Serotonin release measured in the human brain: a PET study with [11C]CIMBI-36 and d-amphetamine challenge. <i>Neuropsychopharmacology</i> , 2020, 45, 804-810.	5.4	34
44	So near yet so far: why won't the UK prescribe medical cannabis?. <i>BMJ Open</i> , 2020, 10, e038687.	1.9	36
45	A Brief History of Psychopharmacology. , 2020, , 1-34.		0
46	Psychiatric Drug Discovery and Development. , 2020, , 35-68.		2
47	Neurotransmission and Mechanisms of Drug Action. , 2020, , 69-123.		0
48	Pharmacodynamics and Pharmacokinetics. , 2020, , 124-150.		0
49	Pharmacogenomics and Psychopharmacology. , 2020, , 151-202.		2
50	Good Clinical Practice in Psychopharmacology. , 2020, , 203-203.		0
51	Drugs to Treat Depression. , 2020, , 227-267.		0
52	Drugs to Treat Anxiety and Insomnia. , 2020, , 268-289.		0
53	Drugs to Treat Schizophrenia and Psychosis (Dopamine Antagonists and Partial Agonists Other Than) Tj ETQq1 1 0.784314 rgBT /Overlo		0
54	Anticonvulsants for Mental Disorders: Valproate, Lamotrigine, Carbamazepine and Oxcarbazepine. , 2020, , 362-391.		0

#	ARTICLE	IF	CITATIONS
55	Drugs to Treat Attention Deficit Hyperactivity Disorder (ADHD). , 2020, , 392-432.		1
56	Drugs to Treat Dementia. , 2020, , 433-453.		0
57	Drugs to Treat Substance Use Disorders. , 2020, , 454-494.		0
58	Electroconvulsive Therapy and Neuromodulation Therapies. , 2020, , 495-495.		0
59	Psychotropic Drug Treatment in Childhood and Adolescence. , 2020, , 525-542.		0
60	Psychotropic Drug Treatment in Later Life. , 2020, , 543-576.		0
61	Psychotropic Prescribing in Pregnancy and Lactation. , 2020, , 577-598.		0
62	The Clinical Management of Acute Disturbance Including Rapid Tranquillisation. , 2020, , 599-618.		0
63	Antipsychotics, Weight Gain and Metabolic Risk. , 2020, , 619-619.		0
64	Medical cannabis in the UK: From principle to practice. Journal of Psychopharmacology, 2020, 34, 931-937.	4.0	27
65	Disturbances across whole brain networks during reward anticipation in an abstinent addiction population. NeuroImage: Clinical, 2020, 27, 102297.	2.7	10
66	The blind men and the elephant: Systematic review of systematic reviews of cannabis use related health harms. European Neuropsychopharmacology, 2020, 33, 1-35.	0.7	90
67	Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression. Journal of Psychopharmacology, 2020, 34, 167-180.	4.0	92
68	Psychedelic Psychiatryâ€™s Brave New World. Cell, 2020, 181, 24-28.	28.9	162
69	DMT alters cortical travelling waves. ELife, 2020, 9, .	6.0	31
70	First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants. BMJ Case Reports, 2019, 12, e230109.	0.5	23
71	Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. Journal of Psychopharmacology, 2019, 33, 1039-1057.	4.0	121
72	Should the supply of cannabis be legalised now?. BMJ: British Medical Journal, 2019, 366, l4473.	2.3	5

#	ARTICLE	IF	CITATIONS
73	British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update. <i>Journal of Psychopharmacology</i> , 2019, 33, 923-947.	4.0	173
74	Manifesto for an international digital mental health network. <i>Digital Psychiatry</i> , 2019, 2, 14-24.	2.1	14
75	Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson's disease: an in vivo ¹¹ C-BU99008 PET study. <i>Brain</i> , 2019, 142, 3116-3128.	7.6	73
76	Tapering of SSRI treatment to mitigate withdrawal symptoms. <i>Lancet Psychiatry</i> , 2019, 6, 560-561.	7.4	3
77	Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin. <i>NeuroImage</i> , 2019, 199, 127-142.	4.2	152
78	Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives. <i>NeuroImage</i> , 2019, 200, 281-291.	4.2	31
79	The Australian drug harms ranking study. <i>Journal of Psychopharmacology</i> , 2019, 33, 759-768.	4.0	91
80	Why medical cannabis is still out of patients' reach: an essay by David Nutt. <i>BMJ: British Medical Journal</i> , 2019, 365, l1903.	2.3	10
81	Alcohol Hangover: Underlying Biochemical, Inflammatory and Neurochemical Mechanisms. <i>Alcohol and Alcoholism</i> , 2019, 54, 196-203.	1.6	43
82	Why Less Is Always More in the Treatment of Alcohol Use Disorders. <i>JAMA Psychiatry</i> , 2019, 76, 359.	11.0	11
83	A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy. <i>Frontiers in Psychiatry</i> , 2019, 10, 138.	2.6	80
84	Compound asset sharing initiatives between pharmaceutical companies, funding bodies, and academia: Learnings and successes. <i>Pharmacology Research and Perspectives</i> , 2019, 7, e00510.	2.4	7
85	Neural correlates of the DMT experience assessed with multivariate EEG. <i>Scientific Reports</i> , 2019, 9, 16324.	3.3	144
86	Naltrexone differentially modulates the neural correlates of motor impulse control in abstinent alcohol-dependent and polysubstance-dependent individuals. <i>European Journal of Neuroscience</i> , 2019, 50, 2311-2321.	2.6	11
87	Psychedelic drugs: a new era in psychiatry?. <i>Dialogues in Clinical Neuroscience</i> , 2019, 21, 139-147.	3.7	70
88	A new approach to formulating and appraising drug policy: A multi-criterion decision analysis applied to alcohol and cannabis regulation. <i>International Journal of Drug Policy</i> , 2018, 56, 144-152.	3.3	44
89	Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2018, 230, 84-86.	4.1	37
90	Psychedelics and related drugs: therapeutic possibilities, mechanisms and regulation. <i>Psychopharmacology</i> , 2018, 235, 373-375.	3.1	12

#	ARTICLE	IF	CITATIONS
91	The hidden therapist: evidence for a central role of music in psychedelic therapy. Psychopharmacology, 2018, 235, 505-519.	3.1	131
92	Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology, 2018, 142, 200-218.	4.1	222
93	Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. Neuropharmacology, 2018, 142, 263-269.	4.1	126
94	Evaluation of ¹¹ C-BU99008, a PET Ligand for the Imidazoline ₂ Binding Site in Human Brain. Journal of Nuclear Medicine, 2018, 59, 1597-1602.	5.0	61
95	Cerebral blood flow predicts differential neurotransmitter activity. Scientific Reports, 2018, 8, 4074.	3.3	78
96	Naltrexone ameliorates functional network abnormalities in alcohol-dependent individuals. Addiction Biology, 2018, 23, 425-436.	2.6	30
97	Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression. Psychopharmacology, 2018, 235, 459-466.	3.1	62
98	Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology, 2018, 235, 399-408.	3.1	537
99	LSD modulates effective connectivity and neural adaptation mechanisms in an auditory oddball paradigm. Neuropharmacology, 2018, 142, 251-262.	4.1	42
100	First evaluation of PET-based human biodistribution and radiation dosimetry of ¹¹ C-BU99008, a tracer for imaging the imidazoline ₂ binding site. EJNMMI Research, 2018, 8, 71.	2.5	12
101	Using Baclofen to Explore GABA-B Receptor Function in Alcohol Dependence: Insights From Pharmacokinetic and Pharmacodynamic Measures. Frontiers in Psychiatry, 2018, 9, 664.	2.6	18
102	GABA _A receptor availability is not altered in adults with autism spectrum disorder or in mouse models. Science Translational Medicine, 2018, 10, .	12.4	41
103	Imaging and Genetic Approaches to Inform Biomarkers for Anxiety Disorders, Obsessive-Compulsive Disorders, and PTSD. Current Topics in Behavioral Neurosciences, 2018, 40, 219-292.	1.7	7
104	Psilocybin and MDMA reduce costly punishment in the Ultimatum Game. Scientific Reports, 2018, 8, 8236.	3.3	25
105	Predicting Responses to Psychedelics: A Prospective Study. Frontiers in Pharmacology, 2018, 9, 897.	3.5	226
106	Psychedelics “ Re-opening the doors of perception. Neuropharmacology, 2018, 142, 1-6.	4.1	5
107	DMT Models the Near-Death Experience. Frontiers in Psychology, 2018, 9, 1424.	2.1	122
108	Cannabis and opioid overdoses: time to move on and examine potential mechanisms. Addiction, 2018, 113, 1551-1552.	3.3	8

#	ARTICLE	IF	CITATIONS
109	Effects of psilocybin therapy on personality structure. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 368-378.	4.5	156
110	Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study. <i>Biological Psychiatry</i> , 2017, 81, 941-948.	1.3	32
111	Toxicological evaluation of 5-methoxy-2-aminoindane (MEAI): Binge mitigating agent in development. <i>Toxicology and Applied Pharmacology</i> , 2017, 319, 59-68.	2.8	6
112	Altered Insula Connectivity under MDMA. <i>Neuropsychopharmacology</i> , 2017, 42, 2152-2162.	5.4	25
113	New ACMD regulations threaten UK's pharmaceutical discovery. <i>Lancet, The</i> , 2017, 389, 2283.	13.7	1
114	Concerns regarding conclusions made about LSD-treatments (received 25 October 2016). <i>History of Psychiatry</i> , 2017, 28, 257-260.	0.3	8
115	Patients' Accounts of Increased "Connectedness" and "Acceptance" After Psilocybin for Treatment-Resistant Depression. <i>Journal of Humanistic Psychology</i> , 2017, 57, 520-564.	2.1	309
116	Evidence for GABA _A receptor dysregulation in gambling disorder: correlation with impulsivity. <i>Addiction Biology</i> , 2017, 22, 1601-1609.	2.6	24
117	Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence. <i>Neuropsychopharmacology</i> , 2017, 42, 1049-1057.	5.4	28
118	Neural substrates of cue reactivity and craving in gambling disorder. <i>Translational Psychiatry</i> , 2017, 7, e992-e992.	4.8	134
119	Inverse agonists "What do they mean for psychiatry?". <i>European Neuropsychopharmacology</i> , 2017, 27, 87-90.	0.7	14
120	A point mutation in the ion conduction pore of AMPA receptor GRIA3 causes dramatically perturbed sleep patterns as well as intellectual disability. <i>Human Molecular Genetics</i> , 2017, 26, 3869-3882.	2.9	35
121	Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. <i>Scientific Reports</i> , 2017, 7, 13187.	3.3	346
122	Serotonin and brain function: a tale of two receptors. <i>Journal of Psychopharmacology</i> , 2017, 31, 1091-1120.	4.0	440
123	Effects of naltrexone are influenced by childhood adversity during negative emotional processing in addiction recovery. <i>Translational Psychiatry</i> , 2017, 7, e1054-e1054.	4.8	18
124	Tripping up addiction: the use of psychedelic drugs in the treatment of problematic drug and alcohol use. <i>Current Opinion in Behavioral Sciences</i> , 2017, 13, 71-76.	3.9	26
125	The ICCAM platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part B: fMRI description. <i>Journal of Psychopharmacology</i> , 2017, 31, 3-16.	4.0	16
126	Acute naltrexone does not remediate fronto-striatal disturbances in alcoholic and alcoholic polysubstance-dependent populations during a monetary incentive delay task. <i>Addiction Biology</i> , 2017, 22, 1576-1589.	2.6	26

#	ARTICLE	IF	CITATIONS
127	Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. World Journal of Biological Psychiatry, 2017, 18, 162-214.	2.6	226
128	A multicenter positron emission tomography study of GABA receptor availability in adults with autism. European Neuropsychopharmacology, 2017, 27, S716-S717.	0.7	0
129	An effective hangover treatment: Friend or foe?. Drug Science, Policy and Law, 2017, 3, 205032451774103.	1.3	17
130	Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. Frontiers in Pharmacology, 2017, 8, 974.	3.5	454
131	Biological markers of generalized anxiety disorder. Dialogues in Clinical Neuroscience, 2017, 19, 147-158.	3.7	72
132	Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI). Frontiers in Human Neuroscience, 2016, 10, 269.	2.0	231
133	Behavioural tasks sensitive to acute abstinence and predictive of smoking cessation success: a systematic review and meta-analysis. Addiction, 2016, 111, 2134-2144.	3.3	15
134	LSD alters eyesâ€closed functional connectivity within the early visual cortex in a retinotopic fashion. Human Brain Mapping, 2016, 37, 3031-3040.	3.6	42
135	Thirty years of <i>Journal of Psychopharmacology</i>. Journal of Psychopharmacology, 2016, 30, 1071-1071.	4.0	0
136	Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future. Journal of Psychopharmacology, 2016, 30, 1163-1164.	4.0	14
137	E-cigarettes are less harmful than smoking. Lancet, The, 2016, 387, 1160-1162.	13.7	41
138	Using [11C]Ro15 4513 PET to characterise GABA-benzodiazepine receptors in opiate addiction: Similarities and differences with alcoholism. NeuroImage, 2016, 132, 1-7.	4.2	10
139	Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry,the, 2016, 3, 619-627.	7.4	988
140	A pilot study of the effect of short-term escitalopram treatment on brain metabolites and gamma-oscillations in healthy subjects. Journal of Psychopharmacology, 2016, 30, 579-580.	4.0	4
141	A placebo-controlled investigation of synaesthesia-like experiences under LSD. Neuropsychologia, 2016, 88, 28-34.	1.6	40
142	Impulsivity in abstinent alcohol and polydrug dependence: a multidimensional approach. Psychopharmacology, 2016, 233, 1487-1499.	3.1	26
143	β -aminobutyric acid as a metabolite: Interpreting magnetic resonance spectroscopy experiments. Journal of Psychopharmacology, 2016, 30, 422-427.	4.0	12
144	Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution. Current Biology, 2016, 26, 1043-1050.	3.9	371

#	ARTICLE	IF	CITATIONS
145	LSD modulates music-induced imagery via changes in parahippocampal connectivity. <i>European Neuropsychopharmacology</i> , 2016, 26, 1099-1109.	0.7	95
146	Neural correlates of the LSD experience revealed by multimodal neuroimaging. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 4853-4858.	7.1	586
147	The paradoxical psychological effects of lysergic acid diethylamide (LSD). <i>Psychological Medicine</i> , 2016, 46, 1379-1390.	4.5	222
148	BAP Position Statement: Off-label prescribing of psychotropic medication to children and adolescents. <i>Journal of Psychopharmacology</i> , 2016, 30, 416-421.	4.0	41
149	Question-based Drug Development for psilocybin – Authors' reply. <i>Lancet Psychiatry</i> , 2016, 3, 807.	7.4	1
150	Whole-genome expression analysis reveals genes associated with treatment response to escitalopram in major depression. <i>European Neuropsychopharmacology</i> , 2016, 26, 1475-1483.	0.7	22
151	Significant reductions in human visual gamma frequency by the gaba reuptake inhibitor tiagabine revealed by robust peak frequency estimation. <i>Human Brain Mapping</i> , 2016, 37, 3882-3896.	3.6	32
152	Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis – motivational hypotheses. <i>Psychopharmacology</i> , 2016, 233, 3537-3552.	3.1	139
153	Semantic activation in LSD: evidence from picture naming. <i>Language, Cognition and Neuroscience</i> , 2016, 31, 1320-1327.	1.2	24
154	Biological markers for anxiety disorders, OCD and PTSD – a consensus statement. Part I: Neuroimaging and genetics. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 321-365.	2.6	118
155	19th biennial IPEG Meeting. <i>Neuropsychiatric Electrophysiology</i> , 2016, 2, .	4.1	0
156	Don't panic. A guide to tryptophan depletion with disorder-specific anxiety provocation. <i>Journal of Psychopharmacology</i> , 2016, 30, 1137-1140.	4.0	5
157	Blunted Endogenous Opioid Release Following an Oral Amphetamine Challenge in Pathological Gamblers. <i>Neuropsychopharmacology</i> , 2016, 41, 1742-1750.	5.4	96
158	Neuroscience-based Nomenclature (NbN) for <i>Journal of Psychopharmacology</i> . <i>Journal of Psychopharmacology</i> , 2016, 30, 413-415.	4.0	35
159	<i>In vivo</i> imaging of microglial activation by positron emission tomography with [¹¹ C]PBR28 in the 5XFAD model of Alzheimer's disease. <i>Glia</i> , 2016, 64, 993-1006.	4.9	71
160	LSD-induced entropic brain activity predicts subsequent personality change. <i>Human Brain Mapping</i> , 2016, 37, 3203-3213.	3.6	240
161	Effect of short-term escitalopram treatment on neural activation during emotional processing. <i>Journal of Psychopharmacology</i> , 2016, 30, 33-39.	4.0	14
162	Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide. <i>Journal of Psychopharmacology</i> , 2016, 30, 344-353.	4.0	113

#	ARTICLE	IF	CITATIONS
163	Validated Method for the Quantification of Baclofen in Human Plasma Using Solid-Phase Extraction and Liquid Chromatography–Tandem Mass Spectrometry. <i>Journal of Analytical Toxicology</i> , 2016, 40, 117-123.	2.8	18
164	Assessment of the quality of brain regions and neuroimaging metrics as biomarkers of Alzheimer’s Disease. <i>EJNMMI Physics</i> , 2015, 2, A46.	2.7	0
165	Optimising ³PET approaches to measuring ⁵HT release in human brain. <i>Synapse</i> , 2015, 69, 505-511.	1.2	15
166	Influence of agonist induced internalization on [³ H]Ro15-4513 binding—an application to imaging fluctuations in endogenous GABA with positron emission tomography. <i>Synapse</i> , 2015, 69, 60-65.	1.2	10
167	Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin. <i>Human Brain Mapping</i> , 2015, 36, 3137-3153.	3.6	196
168	Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. <i>Journal of Psychopharmacology</i> , 2015, 29, 459-525.	4.0	528
169	A Lifetime Prevalence of Comorbidity Between Bipolar Affective Disorder and Anxiety Disorders: A Meta-analysis of 52 Interview-based Studies of Psychiatric Population. <i>EBioMedicine</i> , 2015, 2, 1405-1419.	6.1	78
170	Making a medicine out of MDMA. <i>British Journal of Psychiatry</i> , 2015, 206, 4-6.	2.8	27
171	Harmane: An atypical neurotransmitter?. <i>Neuroscience Letters</i> , 2015, 590, 1-5.	2.1	8
172	Antidepressants and the adolescent brain. <i>Journal of Psychopharmacology</i> , 2015, 29, 545-555.	4.0	39
173	Evidence for serotonin function as a neurochemical difference between fear and anxiety disorders in humans?. <i>Journal of Psychopharmacology</i> , 2015, 29, 1061-1069.	4.0	21
174	Illegal Drugs Laws: Clearing a 50-Year-Old Obstacle to Research. <i>PLoS Biology</i> , 2015, 13, e1002047.	5.6	48
175	Progress in Mind: Focus on Alcohol Use Disorders, an Elsevier Resource Centre. <i>Psychiatry Research</i> , 2015, 226, 513-514.	3.3	7
176	European rating of drug harms. <i>Journal of Psychopharmacology</i> , 2015, 29, 655-660.	4.0	153
177	The dopamine theory of addiction: 40 years of highs and lows. <i>Nature Reviews Neuroscience</i> , 2015, 16, 305-312.	10.2	517
178	Psychopharmacological characterisation of the successive negative contrast effect in rats. <i>Psychopharmacology</i> , 2015, 232, 2697-2709.	3.1	9
179	Distinct Neuropsychological Mechanisms May Explain Delayed- Versus Rapid-Onset Antidepressant Efficacy. <i>Neuropsychopharmacology</i> , 2015, 40, 2165-2174.	5.4	53
180	Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. <i>Nature Genetics</i> , 2015, 47, 717-726.	21.4	310

#	ARTICLE	IF	CITATIONS
181	3-Methyl-methcathinone: Pharmacokinetic profile evaluation in pigs in relation to pharmacodynamics. Journal of Psychopharmacology, 2015, 29, 734-743.	4.0	22
182	Considerations on the role of buprenorphine in recovery from heroin addiction from a UK perspective. Journal of Psychopharmacology, 2015, 29, 43-49.	4.0	4
183	Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. Journal of Psychopharmacology, 2015, 29, 596-607.	4.0	175
184	Ranking the harm of non-medically used prescription opioids in the UK. Regulatory Toxicology and Pharmacology, 2015, 73, 999-1004.	2.7	17
185	The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description. Journal of Psychopharmacology, 2015, 29, 943-960.	4.0	27
186	Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse. Pharmacological Reviews, 2015, 67, 872-1004.	16.0	125
187	LSD enhances the emotional response to music. Psychopharmacology, 2015, 232, 3607-3614.	3.1	115
188	Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men. Journal of Psychopharmacology, 2015, 29, 1085-1091.	4.0	21
189	A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. European Neuropsychopharmacology, 2015, 25, 2318-2325.	0.7	135
190	The European College of Neuropsychopharmacology (ECNP) Medicines Chest Initiative: Rationale and Promise. Pharmaceutical Medicine, 2015, 29, 269-273.	1.9	2
191	Differences between magnetoencephalographic (MEG) spectral profiles of drugs acting on GABA at synaptic and extrasynaptic sites: A study in healthy volunteers. Neuropharmacology, 2015, 88, 155-163.	4.1	34
192	The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level-Dependent Resting State Functional Connectivity. Biological Psychiatry, 2015, 78, 554-562.	1.3	136
193	Antidepressant drug development: Focus on triple monoamine reuptake inhibition. Journal of Psychopharmacology, 2015, 29, 526-544.	4.0	33
194	LSD enhances suggestibility in healthy volunteers. Psychopharmacology, 2015, 232, 785-794.	3.1	207
195	Biological predictors of pharmacological therapy in anxiety disorders. Dialogues in Clinical Neuroscience, 2015, 17, 305-317.	3.7	21
196	8. Neurobiologie des troubles anxieux. , 2014, , 69.		1
197	The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Frontiers in Human Neuroscience, 2014, 8, 20.	2.0	673
198	The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories. International Journal of Neuropsychopharmacology, 2014, 17, 527-540.	2.1	75

#	ARTICLE	IF	CITATIONS
199	Determination of [¹¹ C]PBR28 Binding Potential <i>in vivo</i> : A First Human TSPO Blocking Study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 989-994.	4.3	117
200	In Vivo Imaging of Cerebral Dopamine D3 Receptors in Alcoholism. <i>Neuropsychopharmacology</i> , 2014, 39, 1703-1712.	5.4	53
201	Imaging Endogenous Opioid Peptide Release with [¹¹ C]Carfentanil and [³ H]Diprenorphine: Influence of Agonist-Induced Internalization. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 1604-1612.	4.3	29
202	A randomised trial of the effect of the glycine reuptake inhibitor Org 25935 on cognitive performance in healthy male volunteers. <i>Human Psychopharmacology</i> , 2014, 29, 163-171.	1.5	4
203	Mind-altering drugs and research: from presumptive prejudice to a Neuroscientific Enlightenment?. <i>EMBO Reports</i> , 2014, 15, 208-211.	4.5	11
204	The Hamilton Depression Scale—accelerator or break on antidepressant drug discovery?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 119-120.	1.9	22
205	Allowing for non-adherence to treatment in a randomized controlled trial of two antidepressants (citalopram versus reboxetine): an example from the GENPOD trial. <i>Psychological Medicine</i> , 2014, 44, 2855-2866.	4.5	13
206	Estimating the Harms of Nicotine-Containing Products Using the MCDA Approach. <i>European Addiction Research</i> , 2014, 20, 218-225.	2.4	337
207	Investigating expectation and reward in human opioid addiction with [¹¹ C]-raclopride PET. <i>Addiction Biology</i> , 2014, 19, 1032-1040.	2.6	24
208	Amphetamine induced endogenous opioid release in the human brain detected with [¹¹ C]carfentanil PET: replication in an independent cohort. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 2069-2074.	2.1	85
209	Are multiple physical symptoms a poor prognostic factor or just a marker of depression severity? Secondary analysis of the GenPod trial. <i>Journal of Affective Disorders</i> , 2014, 163, 40-46.	4.1	2
210	A proposal for an updated neuropsychopharmacological nomenclature. <i>European Neuropsychopharmacology</i> , 2014, 24, 1005-1014.	0.7	83
211	Pharmacology should be at the centre of all preclinical and clinical studies on new psychoactive substances (recreational drugs). <i>Journal of Psychopharmacology</i> , 2014, 28, 711-718.	4.0	13
212	Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals. <i>Psychopharmacology</i> , 2014, 231, 2921-2931.	3.1	55
213	Doing it by numbers: A simple approach to reducing the harms of alcohol. <i>Journal of Psychopharmacology</i> , 2014, 28, 3-7.	4.0	60
214	The role of the opioid system in alcohol dependence. <i>Journal of Psychopharmacology</i> , 2014, 28, 8-22.	4.0	67
215	Stratified medicine for mental disorders. <i>European Neuropsychopharmacology</i> , 2014, 24, 5-50.	0.7	152
216	CNS drug development in Europe – Past progress and future challenges. <i>Neurobiology of Disease</i> , 2014, 61, 6-20.	4.4	31

#	ARTICLE	IF	CITATIONS
217	Homological scaffolds of brain functional networks. Journal of the Royal Society Interface, 2014, 11, 20140873.	3.4	415
218	P.6.f.002 Endogenous opioid release in pathological gamblers after an oral amphetamine challenge: a [11C]carfentanil PET study. European Neuropsychopharmacology, 2014, 24, S699-S700.	0.7	1
219	Evaluation of ¹¹ C-BU99008, a PET Ligand for the Imidazoline Binding Sites in Rhesus Brain. Journal of Nuclear Medicine, 2014, 55, 838-844.	5.0	44
220	Attacks on antidepressants: signs of deep-seated stigma?. Lancet Psychiatry, the, 2014, 1, 102-104.	7.4	26
221	Enhanced repertoire of brain dynamical states during the psychedelic experience. Human Brain Mapping, 2014, 35, 5442-5456.	3.6	298
222	Lamotrigine for attention deficit-hyperactivity disorder comorbid with mood disorders: a case series. Journal of Psychopharmacology, 2014, 28, 282-283.	4.0	12
223	Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2014, 28, 403-439.	4.0	511
224	Recommended diagnosis and management of insomnia. The Prescriber, 2014, 25, 12-20.	0.3	1
225	Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2014, 28, 179-203.	4.0	233
226	Acute increases in synaptic GABA detectable in the living human brain: A [11C]Ro15-4513 PET study. NeuroImage, 2014, 99, 158-165.	4.2	42
227	Where now for schizophrenia research?. European Neuropsychopharmacology, 2014, 24, 1181-1187.	0.7	11
228	The influence of different cellular environments on PET radioligand binding: An application to D2/3-dopamine receptor imaging. Neuropharmacology, 2014, 85, 305-313.	4.1	13
229	Deaths from "legal highs": a problem of definitions. Lancet, The, 2014, 383, 952.	13.7	24
230	The extinction of drugs for clinical research: Can the ECNP medicines chest save them?. European Neuropsychopharmacology, 2014, 24, 487-490.	0.7	7
231	The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers. Frontiers in Human Neuroscience, 2014, 8, 204.	2.0	181
232	Was it a vision or a waking dream?. Frontiers in Psychology, 2014, 5, 255.	2.1	26
233	5-HT radioligands for human brain imaging with PET and SPECT. Medicinal Research Reviews, 2013, 33, 54-111.	10.5	138
234	Addiction: lifestyle choice or medical diagnosis?. Journal of Evaluation in Clinical Practice, 2013, 19, 493-496.	1.8	8

#	ARTICLE	IF	CITATIONS
235	A Translational Rodent Assay of Affective Biases in Depression and Antidepressant Therapy. <i>Neuropsychopharmacology</i> , 2013, 38, 1625-1635.	5.4	81
236	Psychiatry's next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders. <i>Journal of Psychopharmacology</i> , 2013, 27, 771-778.	4.0	37
237	Innovative solutions to novel drug development in mental health. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 2438-2444.	6.1	102
238	Benzodiazepines: Risks and benefits. A reconsideration. <i>Journal of Psychopharmacology</i> , 2013, 27, 967-971.	4.0	177
239	Broadband Cortical Desynchronization Underlies the Human Psychedelic State. <i>Journal of Neuroscience</i> , 2013, 33, 15171-15183.	3.6	364
240	Resting state synchrony in anxiety-related circuits of abstinent alcohol-dependent patients. <i>American Journal of Drug and Alcohol Abuse</i> , 2013, 39, 433-440.	2.1	14
241	Amphetamine, past and present – a pharmacological and clinical perspective. <i>Journal of Psychopharmacology</i> , 2013, 27, 479-496.	4.0	431
242	History of cigarette smoking is associated with higher limbic GABAA receptor availability. <i>NeuroImage</i> , 2013, 69, 70-77.	4.2	23
243	Defining Substance Use Disorders: Do We Really Need More Than Heavy Use?. <i>Alcohol and Alcoholism</i> , 2013, 48, 633-640.	1.6	193
244	Noradrenaline – the forgotten amine?. <i>Journal of Psychopharmacology</i> , 2013, 27, 657-658.	4.0	1
245	The effect of 6-week treatment with escitalopram on CCK-4 challenge: A placebo-controlled study in CCK-4-sensitive healthy volunteers. <i>European Neuropsychopharmacology</i> , 2013, 23, 645-652.	0.7	8
246	Generic legislation of new psychoactive drugs. <i>Journal of Psychopharmacology</i> , 2013, 27, 317-324.	4.0	56
247	The brain GABA-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: A pilot [11C]Ro15-4513 positron emission tomography study. <i>Neuropharmacology</i> , 2013, 68, 195-201.	4.1	97
248	Effects of Schedule I drug laws on neuroscience research and treatment innovation. <i>Nature Reviews Neuroscience</i> , 2013, 14, 577-585.	10.2	239
249	The effects of elevated endogenous GABA levels on movement-related network oscillations. <i>NeuroImage</i> , 2013, 66, 36-41.	4.2	148
250	Pharmacological cognitive enhancement in healthy people: Potential and concerns. <i>Neuropharmacology</i> , 2013, 64, 8-12.	4.1	3
251	Functional Connectivity Measures After Psilocybin Inform a Novel Hypothesis of Early Psychosis. <i>Schizophrenia Bulletin</i> , 2013, 39, 1343-1351.	4.3	211
252	The size, burden and cost of disorders of the brain in the UK. <i>Journal of Psychopharmacology</i> , 2013, 27, 761-770.	4.0	163

#	ARTICLE	IF	CITATIONS
253	Stratified medicine in psychiatry: a worrying example or new opportunity in the treatment of anxiety?. Journal of Psychopharmacology, 2013, 27, 119-122.	4.0	16
254	Imaging Imidazoline-I ₂ Binding Sites in Porcine Brain Using ¹¹ C-BU99008. Journal of Nuclear Medicine, 2013, 54, 139-144.	5.0	30
255	Evaluation of the effects of venlafaxine and pregabalin on the carbon dioxide inhalation models of Generalised Anxiety Disorder and panic. Journal of Psychopharmacology, 2013, 27, 135-145.	4.0	11
256	Changes in cardiovascular function after venlafaxine but not pregabalin in healthy volunteers: a double-blind, placebo-controlled study of orthostatic challenge, blood pressure and heart rate. Human Psychopharmacology, 2013, 28, 562-575.	1.5	14
257	Anhedonia revisited: Is there a role for dopamine-targeting drugs for depression?. Journal of Psychopharmacology, 2013, 27, 869-877.	4.0	98
258	New victims of current drug laws. Nature Reviews Neuroscience, 2013, 14, 877-877.	10.2	11
259	Whole-exome sequencing identifies a polymorphism in the BMP5 gene associated with SSRI treatment response in major depression. Journal of Psychopharmacology, 2013, 27, 915-920.	4.0	31
260	Opiate agonists and antagonists modulate taste perception in opiate-maintained and recently detoxified subjects. Journal of Psychopharmacology, 2013, 27, 265-275.	4.0	22
261	Elevating Endogenous GABA Levels with GAT-1 Blockade Modulates Evoked but Not Induced Responses in Human Visual Cortex. Neuropsychopharmacology, 2013, 38, 1105-1112.	5.4	35
262	Effects of 7.5% CO ₂ -Induced Anxiety on Individual Performance During a Group Computer Combat Game. Military Psychology, 2013, 25, 615-622.	1.1	5
263	Can Neuroscience Improve Addiction Treatment and Policies?. Public Health Reviews, 2013, 35, .	3.2	4
264	Personalized Risk Assessment of Drug-Related Harm Is Associated with Health Outcomes. PLoS ONE, 2013, 8, e79754.	2.5	10
265	Opioids Neuroimaging., 2013, , 675-687.		2
266	The effects of 7.5% carbon dioxide inhalation on task performance in healthy volunteers. Journal of Psychopharmacology, 2012, 26, 487-496.	4.0	16
267	Severity of depression and response to antidepressants: GENPOD randomised controlled trial. British Journal of Psychiatry, 2012, 200, 130-136.	2.8	23
268	Popular intoxicants: what lessons can be learned from the last 40 years of alcohol and cannabis regulation?. Journal of Psychopharmacology, 2012, 26, 213-220.	4.0	15
269	Does baseline fatigue influence treatment response to reboxetine or citalopram in depression? An open label randomized controlled trial. Journal of Psychopharmacology, 2012, 26, 663-669.	4.0	6
270	Through a glass darkly: can we improve clarity about mechanism and aims of medications in drug and alcohol treatments?. Journal of Psychopharmacology, 2012, 26, 199-204.	4.0	17

#	ARTICLE	IF	CITATIONS
271	A [¹¹ C]Ro15 4513 PET study suggests that alcohol dependence in man is associated with reduced ± 5 benzodiazepine receptors in limbic regions. Journal of Psychopharmacology, 2012, 26, 273-281.	4.0	47
272	Characterisation of the Contribution of the GABA-Benzodiazepine ± 1 Receptor Subtype to [¹¹ C]Ro15-4513 PET Images. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 731-744.	4.3	33
273	Substitution therapy for alcoholism: time for a reappraisal?. Journal of Psychopharmacology, 2012, 26, 205-212.	4.0	63
274	History of cannabis use is not associated with alterations in striatal dopamine D ₂ /D ₃ receptor availability. Journal of Psychopharmacology, 2012, 26, 144-149.	4.0	57
275	A U-shaped relationship between systolic blood pressure and panic symptoms: the HUNT study. Psychological Medicine, 2012, 42, 1969-1976.	4.5	14
276	Author's reply: "Suppressing addiction using high-dose baclofen, rather than using substitution therapy". Journal of Psychopharmacology, 2012, 26, 1044-1044.	4.0	0
277	Neuroimaging of Serotonin System in Anxiety Disorders. Current Pharmaceutical Design, 2012, 18, 5699-5708.	1.9	33
278	The effect of a clinically effective and non-effective dose of lorazepam on 7.5% CO ₂ -induced anxiety. Human Psychopharmacology, 2012, 27, 540-548.	1.5	10
279	Massive overuse or appropriate medical intervention? The modern-day use of antidepressants. Current Opinion in Pharmacology, 2012, 12, 109-110.	3.5	4
280	GABA system dysfunction in autism and related disorders: From synapse to symptoms. Neuroscience and Biobehavioral Reviews, 2012, 36, 2044-2055.	6.1	346
281	Neuropsychopharmacology across brain diseases. European Neuropsychopharmacology, 2012, 22, 844-846.	0.7	0
282	Elucidation of neurobiology of anxiety disorders in children through pharmacological challenge tests and cortisol measurements: a systematic review. Journal of Psychopharmacology, 2012, 26, 431-442.	4.0	13
283	BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. Journal of Psychopharmacology, 2012, 26, 899-952.	4.0	268
284	The hidden third: improving outcome in treatment-resistant depression. Journal of Psychopharmacology, 2012, 26, 587-602.	4.0	56
285	Influence of different cellular environments on [³ H]DASB radioligand binding. Synapse, 2012, 66, 1035-1039.	1.2	18
286	Evaluation of an operant successive negative contrast task as a method to study affective state in rodents. Behavioural Brain Research, 2012, 234, 155-160.	2.2	19
287	Endogenous Opioid Release in the Human Brain Reward System Induced by Acute Amphetamine Administration. Biological Psychiatry, 2012, 72, 371-377.	1.3	104
288	Striatal dopamine D2/D3 receptor binding in pathological gambling is correlated with mood-related impulsivity. Neurolmage, 2012, 63, 40-46.	4.2	173

#	ARTICLE	IF	CITATIONS
289	On assessing potential efficacy for vortioxetine in generalized anxiety disorder. European Neuropsychopharmacology, 2012, 22, 841-843.	0.7	7
290	Anxiolytics. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 106, 669-679.	1.8	1
291	A plan for mental illness. Nature, 2012, 483, 269-269.	27.8	64
292	Brain Imaging in Addiction. , 2012, , 3-25.		1
293	Evaluation and initial in vitro and ex vivo characterization of the potential positron emission tomography ligand, BU99008 (2-(4,5-dihydro-1 <i>H</i> -imidazol-2-yl)-1-methyl-1 <i>H</i> -indole-3-carboxamide), for the α_2 imidazoline binding site. Synapse, 2012, 66, 542-551.		
294	Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2138-2143.	7.1	789
295	Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. British Journal of Psychiatry, 2012, 200, 238-244.	2.8	170
296	Effects of 7.5% CO ₂ inhalation on allocation of spatial attention to facial cues of emotional expression. Cognition and Emotion, 2011, 25, 626-638.	2.0	20
297	A web-based survey on mephedrone. Drug and Alcohol Dependence, 2011, 118, 19-22.	3.2	225
298	Effects of 7.5% CO ₂ challenge in generalized anxiety disorder. Journal of Psychopharmacology, 2011, 25, 43-51.	4.0	31
299	Perverse effects of the precautionary principle: how banning mephedrone has unexpected implications for pharmaceutical discovery. Therapeutic Advances in Psychopharmacology, 2011, 1, 35-36.	2.7	13
300	Noradrenergic function in generalized anxiety disorder: impact of treatment with venlafaxine on the physiological and psychological responses to clonidine challenge. Journal of Psychopharmacology, 2011, 25, 78-86.	4.0	20
301	GABAergic control of novelty stress-responsive epigenetic and gene expression mechanisms in the rat dentate gyrus. European Neuropsychopharmacology, 2011, 21, 316-324.	0.7	29
302	The full cost and burden of disorders of the brain in Europe exposed for the first time. European Neuropsychopharmacology, 2011, 21, 715-717.	0.7	17
303	Low serotonergic tone and elevated risk for substance misuse. British Journal of Psychiatry, 2011, 199, 353-354.	2.8	3
304	Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial. British Journal of Psychiatry, 2011, 198, 464-471.	2.8	55
305	LET NOT THE BEST BE THE ENEMY OF THE GOOD. Addiction, 2011, 106, 1892-1893.	3.3	23
306	Neuroscience in recession?. Nature Reviews Neuroscience, 2011, 12, 297-302.	10.2	13

#	ARTICLE	IF	CITATIONS
307	Rapid tryptophan depletion following cognitive behavioural therapy for panic disorder. Psychopharmacology, 2011, 213, 593-602.	3.1	7
308	A pilot study of the effectiveness of d-cycloserine during cue-exposure therapy in abstinent alcohol-dependent subjects. Psychopharmacology, 2011, 216, 121-129.	3.1	33
309	Variation in binding affinity of the novel anxiolytic XBD173 for the 18 kDa translocator protein in human brain. Synapse, 2011, 65, 257-259.	1.2	42
310	The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability. Journal of Psychopharmacology, 2011, 25, 1562-1567.	4.0	45
311	No psychiatry without psychopharmacology. British Journal of Psychiatry, 2011, 199, 263-265.	2.8	23
312	Preliminary evidence of anxiolytic effects of the CRF ₁ receptor antagonist R317573 in the 7.5% CO ₂ proof-of-concept experimental model of human anxiety. Journal of Psychopharmacology, 2011, 25, 1199-1206.	4.0	55
313	Gender differences in brain serotonin transporter availability in panic disorder. Journal of Psychopharmacology, 2011, 25, 952-959.	4.0	41
314	Sleep and its disorders in translational medicine. Journal of Psychopharmacology, 2011, 25, 1226-1234.	4.0	23
315	Validating the inhalation of 7.5% CO ₂ in healthy volunteers as a human experimental medicine: a model of generalized anxiety disorder (GAD). Journal of Psychopharmacology, 2011, 25, 1192-1198.	4.0	36
316	Opioids and anxiety. Journal of Psychopharmacology, 2011, 25, 1415-1433.	4.0	85
317	Highlights of the International Consensus Statement on Major Depressive Disorder. Journal of Clinical Psychiatry, 2011, 72, e21.	2.2	12
318	Effects of acute tryptophan depletion in serotonin reuptake inhibitor-remitted patients with generalized anxiety disorder. Psychopharmacology, 2010, 208, 223-232.	3.1	18
319	Dopamine transporter binding in females with panic disorder may vary with clinical status. Journal of Psychiatric Research, 2010, 44, 56-59.	3.1	17
320	SCIENCE AND NON-SCIENCE IN UK DRUG POLICY. Addiction, 2010, 105, 1154-1154.	3.3	5
321	Measuring Endogenous 5-HT Release by Emission Tomography: Promises and Pitfalls. Journal of Cerebral Blood Flow and Metabolism, 2010, 30, 1682-1706.	4.3	132
322	The physical health challenges in patients with severe mental illness: cardiovascular and metabolic risks. Journal of Psychopharmacology, 2010, 24, 1-8.	4.0	11
323	What one hand giveth the other taketh away: some unpredicted effects of enantiomers in psychopharmacology. Journal of Psychopharmacology, 2010, 24, 1137-1141.	4.0	15
324	GABAB Receptors in Addiction and Its Treatment. Advances in Pharmacology, 2010, 58, 373-396.	2.0	99

#	ARTICLE	IF	CITATIONS
325	Antagonist-agonist combinations as therapies for heroin addiction: back to the future?. Journal of Psychopharmacology, 2010, 24, 141-145.	4.0	6
326	The effects of single dose anxiolytic medication on the CO2 models of anxiety: differentiation of subjective and objective measures. Journal of Psychopharmacology, 2010, 24, 649-656.	4.0	23
327	Anxiety - bridging the heart/mind divide. Journal of Psychopharmacology, 2010, 24, 633-638.	4.0	20
328	Microbial infections in eight genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis. Journal of Clinical Pathology, 2010, 63, 156-164.	2.0	76
329	Significant decreases in frontal and temporal [11C]-raclopride binding after THC challenge. Neurolmage, 2010, 52, 1521-1527.	4.2	72
330	British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. Journal of Psychopharmacology, 2010, 24, 1577-1601.	4.0	484
331	Increased serum free tryptophan in patients with diarrhea-predominant irritable bowel syndrome. Nutrition Research, 2010, 30, 678-688.	2.9	35
332	Voluntary exercise alters GABAA receptor subunit and glutamic acid decarboxylase-67 gene expression in the rat forebrain. Journal of Psychopharmacology, 2010, 24, 745-756.	4.0	52
333	Nutt damage – Author's reply. Lancet, The, 2010, 375, 724.	13.7	16
334	Vienna Declaration: a call for evidence-based drug policies. Lancet, The, 2010, 376, 310-312.	13.7	89
335	Drug harms in the UK: a multicriteria decision analysis. Lancet, The, 2010, 376, 1558-1565.	13.7	1,201
336	Harms associated with psychoactive substances: findings of the UK National Drug Survey. Journal of Psychopharmacology, 2010, 24, 147-153.	4.0	70
337	The role and basis of the drug laws. Prometheus, 2010, 28, 293-297.	0.4	2
338	Searching for perfect sleep: the continuing evolution of GABA _A receptor modulators as hypnotics. Journal of Psychopharmacology, 2010, 24, 1601-1612.	4.0	134
339	User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study. Journal of Substance Use, 2010, 15, 283-300.	0.7	69
340	Rationale for, Barriers to, and Appropriate Medication for the Long-Term Treatment of Depression. Journal of Clinical Psychiatry, 2010, 71, e02.	2.2	17
341	International Consensus Statement on Major Depressive Disorder. Journal of Clinical Psychiatry, 2010, 71, e08.	2.2	47
342	Current and former ecstasy users report different sleep to matched controls: a web-based questionnaire study. Journal of Psychopharmacology, 2009, 23, 249-257.	4.0	21

#	ARTICLE	IF	CITATIONS
343	A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO2 models of experimental human anxiety. Journal of Psychopharmacology, 2009, 23, 117-122.	4.0	42
344	That warm fuzzy feeling: brain serotonergic neurons and the regulation of emotion. Journal of Psychopharmacology, 2009, 23, 392-400.	4.0	74
345	Beyond psychoanaleptics “can we improve antidepressant drug nomenclature?”. Journal of Psychopharmacology, 2009, 23, 343-345.	4.0	44
346	Prescribing antidepressants post Cipriani et al. Journal of Psychopharmacology, 2009, 23, 865-866.	4.0	7
347	Identification of an imidazoline binding protein: Creatine kinase and an imidazoline-2 binding site. Brain Research, 2009, 1279, 21-28.	2.2	32
348	Emotional symptoms in children: The effect of maternal depression, life events, and COMT genotype. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009, 150B, 209-218.	1.7	21
349	Effects of stressful life events, maternal depression and 5-HTTLPR genotype on emotional symptoms in pre-adolescent children. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009, 150B, 670-682.	1.7	53
350	Cardiac slowing and acute tryptophan depletion: a comment on the paper by van der Veen et al.. Psychopharmacology, 2009, 203, 831-833.	3.1	1
351	Equivalent effects of acute tryptophan depletion on REM sleep in ecstasy users and controls. Psychopharmacology, 2009, 206, 187-196.	3.1	14
352	Redistribution of slow wave activity of sleep during pharmacological treatment of depression with paroxetine but not with nefazodone. Journal of Sleep Research, 2009, 18, 342-348.	3.2	16
353	The Pharmacology of Anxiety. Current Topics in Behavioral Neurosciences, 2009, 2, 303-330.	1.7	50
354	Characterisation of the effects of caffeine on sleep in the rat: a potential model of sleep disruption. Journal of Psychopharmacology, 2009, 23, 475-486.	4.0	29
355	Serotonin and Sensitivity to Trauma-Related Exposure in Selective Serotonin Reuptake Inhibitors-Recovered Posttraumatic Stress Disorder. Biological Psychiatry, 2009, 66, 17-24.	1.3	42
356	Introducing the Pharmacology Behind Treatments to Understand Treatment Challenges. European Psychiatry, 2009, 24, .	0.2	0
357	Effects on sleep stages and microarchitecture of caffeine and its combination with zolpidem or trazodone in healthy volunteers. Journal of Psychopharmacology, 2009, 23, 487-494.	4.0	28
358	Antidepressant-induced jitteriness/anxiety syndrome: systematic review. British Journal of Psychiatry, 2009, 194, 483-490.	2.8	160
359	Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. European Neuropsychopharmacology, 2009, 19, 451-456.	0.7	61
360	Brain opioid receptor binding in early abstinence from alcohol dependence and relationship to craving: An [11C]diprenorphine PET study. European Neuropsychopharmacology, 2009, 19, 740-748.	0.7	61

#	ARTICLE	IF	CITATIONS
361	Government vs science over drug and alcohol policy. <i>Lancet</i> , 2009, 374, 1731-1733.	13.7	15
362	Women with diarrhoea-predominant irritable bowel syndrome show an increased pressure response to 35% carbon dioxide stress challenge. <i>Stress</i> , 2009, 12, 30-36.	1.8	7
363	Equasay " An overlooked addiction with implications for the current debate on drug harms. <i>Journal of Psychopharmacology</i> , 2009, 23, 3-5.	4.0	87
364	Effects of acute tyrosine/phenylalanine depletion on the selective processing of smoking-related cues and the relative value of cigarettes in smokers. <i>Psychopharmacology</i> , 2008, 196, 611-621.	3.1	51
365	Mourning and melancholia revisited: correspondences between principles of Freudian metapsychology and empirical findings in neuropsychiatry. <i>Annals of General Psychiatry</i> , 2008, 7, 9.	2.7	81
366	GENetic and clinical Predictors Of treatment response in Depression: the GenPod randomised trial protocol. <i>Trials</i> , 2008, 9, 29.	1.6	23
367	Addiction: the clinical interface. <i>British Journal of Pharmacology</i> , 2008, 154, 397-405.	5.4	39
368	Does alcohol increase the risk of overdose death: the need for a translational approach. <i>Addiction</i> , 2008, 103, 1060-1062.	3.3	67
369	UNDERSTANDING CAUSAL PATHWAYS: A RESPONSE TO THE COMMENTARIES. <i>Addiction</i> , 2008, 103, 1067-1068.	3.3	2
370	Is the association of hypertension and panic disorder explained by clustering of autonomic panic symptoms in hypertensive patients?. <i>Journal of Affective Disorders</i> , 2008, 111, 344-350.	4.1	9
371	GABA-A receptors and the response to CO2 inhalation " A translational trans-species model of anxiety?. <i>Pharmacology Biochemistry and Behavior</i> , 2008, 90, 51-57.	2.9	23
372	Chapter 5.1 Phenomenology of anxiety disorders. <i>Handbook of Behavioral Neuroscience</i> , 2008, , 365-393.	0.7	8
373	Reduced thalamic grey matter volume in opioid dependence is influenced by degree of alcohol use: a voxel-based morphometry study. <i>Journal of Psychopharmacology</i> , 2008, 22, 7-10.	4.0	32
374	Why does the world have such a `down' on antidepressants?. <i>Journal of Psychopharmacology</i> , 2008, 22, 223-226.	4.0	13
375	Uncritical positive regard? Issues in the efficacy and safety of psychotherapy. <i>Journal of Psychopharmacology</i> , 2008, 22, 3-6.	4.0	93
376	Assessment of GABAABenzodiazepine Receptor (GBzR) Sensitivity in Patients with Alcohol Dependence. <i>Alcohol and Alcoholism</i> , 2008, 43, 614-618.	1.6	12
377	Reply to letter by Green, Marsden and Fone (2007) about Sessa and Nutt's editorial (MDMA: baby with) Tj ETQq1 1.0.784314 rgBT /Ove	4.0	3
378	Reply to OCD letter. <i>Journal of Psychopharmacology</i> , 2008, 22, 338-338.	4.0	1

#	ARTICLE	IF	CITATIONS
379	Gene Expression Subtypes in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. Journal of Infectious Diseases, 2008, 197, 1171-1184.	4.0	113
380	Introduction. The neurobiology of drug addiction: new vistas. Philosophical Transactions of the Royal Society B: Biological Sciences, 2008, 363, 3109-3111.	4.0	12
381	Establishing non-inferiority in treatment trials in psychiatry – guidelines from an Expert Consensus Meeting. Journal of Psychopharmacology, 2008, 22, 409-416.	4.0	24
382	Serotonin 5-HT _{1A} receptor binding in people with panic disorder: positron emission tomography study. British Journal of Psychiatry, 2008, 193, 229-234.	2.8	166
383	Brain dopamine response in human opioid addiction. British Journal of Psychiatry, 2008, 193, 65-72.	2.8	64
384	Potential Novel Anxiolytic Drugs. Current Pharmaceutical Design, 2008, 14, 3534-3546.	1.9	35
385	Tryptophan Research in Panic Disorder. International Journal of Tryptophan Research, 2008, 1, IJTR.S929.	2.3	4
386	Low Sensitivity of the Positron Emission Tomography Ligand [11C]Diprenorphine to Agonist Opiates. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 661-667.	2.5	28
387	Rob Kerwin – an appreciation. Journal of Psychopharmacology, 2007, 21, 237-237.	4.0	1
388	Panic and hypertension: brothers in arms through 5-HT?. Journal of Psychopharmacology, 2007, 21, 563-566.	4.0	26
389	A validation of the 7.5% CO ₂ model of GAD using paroxetine and lorazepam in healthy volunteers. Journal of Psychopharmacology, 2007, 21, 42-49.	4.0	80
390	MDMA, politics and medical research: Have we thrown the baby out with the bathwater?. Journal of Psychopharmacology, 2007, 21, 787-791.	4.0	39
391	Development and validation of the Generalized Anxiety Disorder Inventory (GADI). Journal of Psychopharmacology, 2007, 21, 145-152.	4.0	24
392	Management of insomnia: treatments and mechanisms. British Journal of Psychiatry, 2007, 191, 195-197.	2.8	26
393	Which antidepressants have demonstrated superior efficacy? A review of the evidence. International Clinical Psychopharmacology, 2007, 22, 323-329.	1.7	137
394	In vitro and in vivo effect of BU99006 (5-isothiocyano-2-benzofuranyl-2-imidazoline) on I ₂ binding in relation to MAO: Evidence for two distinct I ₂ binding sites. Neuropharmacology, 2007, 52, 395-404.	4.1	13
395	Blockade of alcohol's amnestic activity in humans by an α 5 subtype benzodiazepine receptor inverse agonist. Neuropharmacology, 2007, 53, 810-820.	4.1	103
396	Development of a rational scale to assess the harm of drugs of potential misuse. Lancet, The, 2007, 369, 1047-1053.	13.7	1,040

#	ARTICLE	IF	CITATIONS
397	Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2007, 21, 10-41.	4.0	232
398	The effect of 1-(4,5-dihydro-1H-imidazol-2-yl) isoquinoline on monoamine release and turnover in the rat frontal cortex. <i>Neuroscience Letters</i> , 2007, 422, 109-113.	2.1	2
399	Seizures in a night club. <i>Lancet, The</i> , 2007, 370, 220.	13.7	10
400	The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. <i>Journal of Psychopharmacology</i> , 2007, 21, 461-471.	4.0	311
401	Brain opioid receptor binding in early abstinence from opioid dependence. <i>British Journal of Psychiatry</i> , 2007, 191, 63-69.	2.8	68
402	Role of GABA in anxiety and depression. <i>Depression and Anxiety</i> , 2007, 24, 495-517.	4.1	416
403	The effect of nicotine on striatal dopamine release in man: A [11C]raclopride PET study. <i>Synapse</i> , 2007, 61, 637-645.	1.2	87
404	Pharmacological treatment of bipolar disorder. <i>Psychiatry (Abingdon, England)</i> , 2007, 6, 305-308.	0.2	4
405	A translational, caffeine-induced model of onset insomnia in rats and healthy volunteers. <i>Psychopharmacology</i> , 2007, 191, 943-950.	3.1	50
406	d-Cycloserine and performance under different states of anxiety in healthy volunteers. <i>Psychopharmacology</i> , 2007, 193, 579-585.	3.1	30
407	Alcohol alternatives â€“ a goal for psychopharmacology?. <i>Journal of Psychopharmacology</i> , 2006, 20, 318-320.	4.0	19
408	Generalized anxiety disorder: A comorbid disease. <i>European Neuropsychopharmacology</i> , 2006, 16, S109-S118.	0.7	72
409	Resolution of Sleepiness and Fatigue in Major Depressive Disorder: A Comparison of Bupropion and the Selective Serotonin Reuptake Inhibitors. <i>Biological Psychiatry</i> , 2006, 60, 1350-1355.	1.3	296
410	In vitro and ex vivo distribution of [3H]harmaline, an endogenous β^2 -carboline, in rat brain. <i>Neuropharmacology</i> , 2006, 50, 269-276.	4.1	53
411	Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. <i>Trends in Pharmacological Sciences</i> , 2006, 27, 402-409.	8.7	1,237
412	GABA<sub>A</sub> Receptors: Subtypes, Regional Distribution, and Function. <i>Journal of Clinical Sleep Medicine</i> , 2006, 02, .	2.6	100
413	Depleting Serotonin Enhances Both Cardiovascular and Psychological Stress Reactivity in Recovered Patients With Anxiety Disorders. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 414-418.	1.4	48
414	Imaging alcohol cue exposure in alcohol dependence using a PET15O-H2O paradigm: results from a pilot study. <i>Addiction Biology</i> , 2006, 11, 107-115.	2.6	21

#	ARTICLE	IF	CITATIONS
415	Autoradiographical distribution of imidazoline binding sites in monoamine oxidase A deficient mice. Journal of Neurochemistry, 2006, 96, 1551-1559.	3.9	18
416	2-(4,5-Dihydroimidazol-2-yl)benzimidazoles as highly selective imidazoline I2/adrenergic α_2 receptor ligands. Bioorganic and Medicinal Chemistry, 2006, 14, 6679-6685.	3.0	7
417	Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram. Psychopharmacology, 2006, 186, 107-112.	3.1	15
418	A tale of two Es. Journal of Psychopharmacology, 2006, 20, 315-317.	4.0	23
419	Human Taste Thresholds Are Modulated by Serotonin and Noradrenaline. Journal of Neuroscience, 2006, 26, 12664-12671.	3.6	171
420	Acute Tryptophan Depletion Alters Gastrointestinal and Anxiety Symptoms in Irritable Bowel Syndrome. American Journal of Gastroenterology, 2006, 101, 2582-2587.	0.4	33
421	Anxiety and OCD – the chicken or the egg?. Journal of Psychopharmacology, 2006, 20, 729-731.	4.0	20
422	Dopamine and social anxiety disorder. Revista Brasileira De Psiquiatria, 2006, 28, .	1.7	0
423	The role of dopamine and norepinephrine in depression and antidepressant treatment. Journal of Clinical Psychiatry, 2006, 67 Suppl 6, 3-8.	2.2	53
424	Consensus statement and research needs: the role of dopamine and norepinephrine in depression and antidepressant treatment. Journal of Clinical Psychiatry, 2006, 67 Suppl 6, 46-9.	2.2	11
425	GABAA receptors: subtypes, regional distribution, and function. Journal of Clinical Sleep Medicine, 2006, 2, S7-11.	2.6	50
426	Overview of Diagnosis and Drug Treatments of Anxiety Disorders. CNS Spectrums, 2005, 10, 49-56.	1.2	159
427	Behavioral and cardiovascular effects of 7.5% CO2 in human volunteers. Depression and Anxiety, 2005, 21, 18-25.	4.1	116
428	GABA-benzodiazepine receptor function in alcohol dependence: a combined 11C-flumazenil PET and pharmacodynamic study. Psychopharmacology, 2005, 180, 595-606.	3.1	47
429	IS THERE COGNITIVE IMPAIRMENT IN CLINICALLY “HEALTHY” ABSTINENT ALCOHOL DEPENDENCE?. Alcohol and Alcoholism, 2005, 40, 498-503.	1.6	92
430	NICE: The National Institute of Clinical Excellence - or Eccentricity? Reflections on the Z-drugs as hypnotics. Journal of Psychopharmacology, 2005, 19, 125-127.	4.0	19
431	Using [11C]Diprenorphine to Image Opioid Receptor Occupancy by Methadone in Opioid Addiction: Clinical and Preclinical Studies. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 309-315.	2.5	66
432	Gamma hydroxy butyrate abuse and dependency. Journal of Psychopharmacology, 2005, 19, 195-204.	4.0	102

#	ARTICLE	IF	CITATIONS
433	Death by tricyclic: the real antidepressant scandal?. Journal of Psychopharmacology, 2005, 19, 123-124.	4.0	38
434	The use of sleep measures to compare a new 5HT1A agonist with buspirone in humans. Journal of Psychopharmacology, 2005, 19, 609-613.	4.0	33
435	Acute Tryptophan Depletion. Part I: Rationale and Methodology. Australian and New Zealand Journal of Psychiatry, 2005, 39, 558-564.	2.3	114
436	Acute Tryptophan Depletion. Part II: Clinical Effects and Implications. Australian and New Zealand Journal of Psychiatry, 2005, 39, 565-574.	2.3	93
437	Making sense of GABAA receptor subtypes: is a new nomenclature needed?. Journal of Psychopharmacology, 2005, 19, 219-220.	4.0	17
438	Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. Current Opinion in Pharmacology, 2005, 5, 87-93.	3.5	106
439	Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2005, 19, 567-596.	4.0	537
440	Acute tryptophan depletion. Part I: rationale and methodology. Australian and New Zealand Journal of Psychiatry, 2005, 39, 558-564.	2.3	12
441	Acute tryptophan depletion. Part II: clinical effects and implications. Australian and New Zealand Journal of Psychiatry, 2005, 39, 565-574.	2.3	8
442	Evidence-Based Guidelines for the Pharmacological Management of Substance Misuse, Addiction and Comorbidity: Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2004, 18, 293-335.	4.0	160
443	Invited review: the evolution of antidepressant mechanisms. Fundamental and Clinical Pharmacology, 2004, 18, 1-21.	1.9	158
444	The clinical use of buprenorphine in opiate addiction: evidence and practice. Acta Neuropsychiatrica, 2004, 16, 246-274.	2.1	21
445	Acute Carbon Dioxide Exposure in Healthy Adults: Evaluation of a Novel Means of Investigating the Stress Response. Journal of Neuroendocrinology, 2004, 16, 256-264.	2.6	101
446	Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder. Biological Psychiatry, 2004, 56, 503-509.	1.3	84
447	Harmane and Harmalan Are Bioactive Components of Classical Clonidine-Displacing Substanceâ€¢. Biochemistry, 2004, 43, 16385-16392.	2.5	36
448	Using sleep to evaluate comparative serotonergic effects of paroxetine and citalopram. European Neuropsychopharmacology, 2004, 14, 367-372.	0.7	30
449	Using saccadic eye movements as objective measures of tolerance in methadone dependent individuals during the hydromorphone challenge test. Addiction Biology, 2003, 8, 59-66.	2.6	13
450	Endogenous Â-Carbolines as Clonidine-Displacing Substances. Annals of the New York Academy of Sciences, 2003, 1009, 157-166.	3.8	43

#	ARTICLE	IF	CITATIONS
451	Characterization of [3H]Harmaline Binding to Rat Whole Brain Membranes. Annals of the New York Academy of Sciences, 2003, 1009, 175-179.	3.8	14
452	Relationship Between Imidazoline2 Sites and Monoamine Oxidase. Annals of the New York Academy of Sciences, 2003, 1009, 353-356.	3.8	7
453	Identification of an I2 Binding Protein From Rabbit Brain. Annals of the New York Academy of Sciences, 2003, 1009, 364-366.	3.8	7
454	In Vivo Estimation of Imidazoline2 Binding Site Turnover. Annals of the New York Academy of Sciences, 2003, 1009, 367-370.	3.8	6
455	Behavioral, neuroendocrine and neurochemical effects of the imidazoline I2 receptor selective ligand BU224 in naive rats and rats exposed to the stress of the forced swim test. Psychopharmacology, 2003, 167, 195-202.	3.1	45
456	2-(4,5-Dihydro-1H-imidazol-2-yl)indazole (indazim) derivatives as selective I2 imidazoline receptor ligands. European Journal of Pharmaceutical Sciences, 2003, 20, 201-208.	4.0	28
457	Naloxone displacement at opioid receptor sites measured in vivo in the human brain. European Journal of Pharmacology, 2003, 459, 217-219.	3.5	40
458	Functional connectivity analysis of the neural circuits of opiate craving: 'more' rather than 'different'. NeuroImage, 2003, 20, 1964-1970.	4.2	78
459	Increased sympathetic response to standing in panic disorder. Psychiatry Research, 2003, 118, 69-79.	3.3	46
460	Drugs of Abuse John Q. Wang Humana Press. ISBN: 1-588-29057-3, 2003, 505 pp. with index, \$135.00. Journal of Substance Use, 2003, 8, 279-279.	0.7	0
461	Neurobiology of addiction and implications for treatment. British Journal of Psychiatry, 2003, 182, 97-100.	2.8	90
462	Does the Brain Noradrenaline Network Mediate the Effects of the CO2 Challenge?. Journal of Psychopharmacology, 2003, 17, 252-259.	4.0	73
463	Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism. Neurology, 2003, 61, 1161-1161.	1.1	25
464	New directions in the treatment of anxiety disorders. Expert Opinion on Therapeutic Patents, 2003, 13, 401-423.	5.0	6
465	Death and Dependence: Current Controversies over the Selective Serotonin Reuptake Inhibitors. Journal of Psychopharmacology, 2003, 17, 355-364.	4.0	69
466	The Unhappy Saga of 'Happy Pills'. Journal of Psychopharmacology, 2003, 17, 251-251.	4.0	6
467	Generalized anxiety disorder: comorbidity, comparative biology and treatment. International Journal of Neuropsychopharmacology, 2002, 5, 315-325.	2.1	102
468	Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. Journal of Psychopharmacology, 2002, 16, 5-14.	4.0	87

#	ARTICLE	IF	CITATIONS
469	The neuropharmacology of serotonin and noradrenaline in depression. International Clinical Psychopharmacology, 2002, 17, S1-S12.	1.7	185
470	Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. British Journal of Psychiatry, 2002, 180, 528-535.	2.8	73
471	5-Isothiocyanato-2-benzofuranyl-2-imidazoline (BU99006) an irreversible imidazoline2 binding site ligand: in vitro and in vivo characterisation in rat brain. Neuropharmacology, 2002, 43, 75-83.	4.1	14
472	Distribution of [3H]BU224, a selective imidazoline I2 binding site ligand, in rat brain. European Journal of Pharmacology, 2002, 450, 55-60.	3.5	16
473	Inhalation of 35% CO2 results in activation of the HPA axis in healthy volunteers. Psychoneuroendocrinology, 2002, 27, 715-729.	2.7	92
474	Imaging the GABA-Benzodiazepine Receptor Subtype Containing the α 5-Subunit In Vivo with [11C]Ro15 4513 Positron Emission Tomography. Journal of Cerebral Blood Flow and Metabolism, 2002, 22, 878-889.	4.3	113
475	α 2-carboline binding to imidazoline receptors. Drug and Alcohol Dependence, 2001, 64, 203-208.	3.2	118
476	Changes in Regional Cerebral Blood Flow Elicited by Craving Memories in Abstinent Opiate-Dependent Subjects. American Journal of Psychiatry, 2001, 158, 1680-1686.	7.2	151
477	Tryptophan depletion and its implications for psychiatry. British Journal of Psychiatry, 2001, 178, 399-405.	2.8	246
478	New insights into the role of the GABA α 1 benzodiazepine receptor in psychiatric disorder. British Journal of Psychiatry, 2001, 179, 390-396.	2.8	295
479	Venlafaxine occupation at the noradrenaline reuptake site: in-vivo determination in healthy volunteers. Journal of Psychopharmacology, 2001, 15, 9-12.	4.0	30
480	Flumazenil challenge in social phobia. , 2000, 11, 27-30.		27
481	Probes for imidazoline binding sites: synthesis and evaluation of a selective, irreversible I 2 ligand. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 605-607.	2.2	15
482	The psychobiology of anxiolytic drugs. , 2000, 88, 197-212.		85
483	The psychobiology of anxiolytic drugs. , 2000, 88, 213-227.		103
484	Sleep changes during long-term treatment of depression with fluvoxamine - a home-based study. Psychopharmacology, 2000, 149, 360-365.	3.1	40
485	Evaluation of [O-methyl - 11 C]RS-15385-197 as a positron emission tomography radioligand for central α 2-adrenoceptors. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 475-484.	6.4	20
486	Sleep and daytime sleepiness the next day following single night-time dose of fluvoxamine, dothiepin and placebo in normal volunteers. Journal of Psychopharmacology, 2000, 14, 378-386.	4.0	26

#	ARTICLE	IF	CITATIONS
487	Treatment of depression and concomitant anxiety. <i>European Neuropsychopharmacology</i> , 2000, 10, S433-S437.	0.7	39
488	The psychobiology of posttraumatic stress disorder. <i>Journal of Clinical Psychiatry</i> , 2000, 61 Suppl 5, 24-9; discussion 30-2.	2.2	16
489	Maintenance pharmacotherapy of unipolar depression. <i>Psychiatric Bulletin</i> , 1999, 23, 370-373.	0.3	2
490	Alcohol and the brain. <i>British Journal of Psychiatry</i> , 1999, 175, 114-119.	2.8	97
491	Novel Selective Compounds for the Investigation of Imidazoline Receptorsa. <i>Annals of the New York Academy of Sciences</i> , 1999, 881, 81-91.	3.8	72
492	Comparison of Crude Methanolic CDS Extracts from Various Tissues. <i>Annals of the New York Academy of Sciences</i> , 1999, 881, 92-96.	3.8	5
493	Inhibition of Central Monoamine Oxidase by Imidazoline2 Site-Selective Ligands. <i>Annals of the New York Academy of Sciences</i> , 1999, 881, 114-117.	3.8	37
494	Autoradiography of I2 Receptors in Frog Brain. <i>Annals of the New York Academy of Sciences</i> , 1999, 881, 208-211.	3.8	2
495	Assessment of GABA A benzodiazepine receptor (GBzR) sensitivity in patients on benzodiazepines. <i>Psychopharmacology</i> , 1999, 146, 180-184.	3.1	14
496	Anti-oxidant vitamins and mental performance of the elderly. <i>Human Psychopharmacology</i> , 1999, 14, 459-471.	1.5	34
497	The neurobiology of social phobia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1999, 249, S11-S18.	3.2	45
498	The use of benzodiazepines in anxiety and other disorders. <i>European Neuropsychopharmacology</i> , 1999, 9, S407-S412.	0.7	63
499	Paroxetine and its uses in psychiatry. <i>British Journal of Hospital Medicine</i> , 1999, 60, 353-356.	0.2	2
500	Care of depressed patients with anxiety symptoms. <i>Journal of Clinical Psychiatry</i> , 1999, 60 Suppl 17, 23-7; discussion 46-8.	2.2	8
501	Characterisation and localisation of [12-(2-benzofuranyl)-2-imidazoline binding in rat brain: a selective ligand for imidazoline I2 receptors. <i>European Journal of Pharmacology</i> , 1998, 353, 123-135.	3.5	82
502	`Seeing through a glass darkly': casting light on imidazoline `I' sites. <i>Trends in Pharmacological Sciences</i> , 1998, 19, 381-390.	8.7	238
503	Decreased Brain GABAA-Benzodiazepine Receptor Binding in Panic Disorder. <i>Archives of General Psychiatry</i> , 1998, 55, 715.	12.3	344
504	Serotonin and panic. <i>British Journal of Psychiatry</i> , 1998, 172, 465-471.	2.8	94

#	ARTICLE	IF	CITATIONS
505	Efficacy of mirtazapine in clinically relevant subgroups of depressed patients. <i>Depression and Anxiety</i> , 1998, 7 Suppl 1, 7-10.	4.1	2
506	Noradrenergic mechanisms in the prefrontal cortex. <i>Journal of Psychopharmacology</i> , 1997, 11, 163-168.	4.0	51
507	Adult night terrors and paroxetine. <i>Lancet, The</i> , 1997, 350, 185.	13.7	47
508	The feasibility of abrupt methadone-buprenorphine transfer in British opiate addicts in an outpatient setting. <i>Addiction Biology</i> , 1997, 2, 191-200.	2.6	27
509	A pilot controlled study of the effects of flumazenil in posttraumatic stress disorder. <i>Biological Psychiatry</i> , 1997, 41, 988-990.	1.3	35
510	Identification of ligands selective for central I2-imidazoline binding sites. <i>Neurochemistry International</i> , 1997, 30, 47-53.	3.8	39
511	Imagery of craving in opiate addicts undergoing detoxification. <i>Drug and Alcohol Dependence</i> , 1997, 48, 25-31.	3.2	27
512	Mirtazapine: pharmacology in relation to adverse effects. <i>Acta Psychiatrica Scandinavica</i> , 1997, 96, 31-37.	4.5	64
513	Anhedonia and chronic mild stress model in depression. <i>Psychopharmacology</i> , 1997, 134, 333-336.	3.1	33
514	Case History 3. <i>Human Psychopharmacology</i> , 1997, 12, S39-S40.	1.5	72
515	The Neurochemistry of Addiction. <i>Human Psychopharmacology</i> , 1997, 12, S53-S58.	1.5	14
516	The Neurochemistry of Addiction. <i>Human Psychopharmacology</i> , 1997, 12, S53-S58.	1.5	1
517	<i>Psychopharmacology: An Introduction</i> (3rd edn). By RenÅ© Spiegel. Chichester: John Wiley. 1996. 295 pp. Å£45 (hb). ISBN: 0 471 95729 1. <i>British Journal of Psychiatry</i> , 1997, 170, 96-96.	2.8	0
518	Practical pharmacotherapy for anxiety disorders. <i>Advances in Psychiatric Treatment</i> , 1997, 3, 65-65.	0.5	0
519	Management of patients with depression associated with anxiety symptoms. <i>Journal of Clinical Psychiatry</i> , 1997, 58 Suppl 8, 11-6.	2.2	8
520	Noradrenaline in depression: half a century of progress. <i>Journal of Psychopharmacology</i> , 1997, 11, S3.	4.0	4
521	[3H]2-(2-Benzofuranyl)-2-imidazoline: a new selective high affinity radioligand for the study of rabbit brain imidazoline I2 receptors. <i>European Journal of Pharmacology</i> , 1996, 304, 221-229.	3.5	52
522	Imidazoline binding sites in Huntington's and Parkinson's disease putamen. <i>European Journal of Pharmacology</i> , 1996, 301, R19-R21.	3.5	43

#	ARTICLE	IF	CITATIONS
523	Addiction: brain mechanisms and their treatment implications. Lancet, The, 1996, 347, 31-36.	13.7	104
524	Benzodiazepine Site Pharmacokinetic/Pharmacodynamic Quantification in Man: Direct Measurement of Drug Occupancy and Effects on the Human Brain In Vivo. Neuropharmacology, 1996, 35, 1483-1491.	4.1	45
525	Moclobemide in the treatment of social phobia. International Clinical Psychopharmacology, 1996, 11, 77-82.	1.7	28
526	Role of GABA in memory and anxiety. , 1996, 4, 100-110.		95
527	Noradrenaline and attention lapses. Nature, 1996, 380, 291-291.	27.8	149
528	The psychopharmacology of anxiety. British Journal of Hospital Medicine, 1996, 55, 187-91.	0.0	0
529	A comparison of the effects of phenelzine treatment with moclobemide treatment on cardiovascular reflexes. International Clinical Psychopharmacology, 1995, 10, 229-238.	1.7	12
530	Psychopharmacology of benzodiazepines—an update. Human Psychopharmacology, 1995, 10, S1-S14.	1.5	5
531	The effects of clonidine on cardiovascular responses to standing in healthy volunteers. Clinical Autonomic Research, 1995, 5, 171-177.	2.5	26
532	Functional Studies of Specific Imidazoline-2 Receptor Ligands. Annals of the New York Academy of Sciences, 1995, 763, 125-139.	3.8	121
533	Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites. Journal of Pharmacology and Experimental Therapeutics, 1995, 272, 681-8.	2.5	71
534	A pharmacodynamic study of the α_2 -adrenergic receptor antagonist ethoxydazoxan in healthy volunteers. Clinical Pharmacology and Therapeutics, 1994, 56, 420-429.	4.7	16
535	Anxiolytic Potential of Benzodiazepine Receptor Partial Agonists. CNS Drugs, 1994, 1, 305-315.	5.9	34
536	Alcohol: the drug. British Medical Bulletin, 1994, 50, 5-17.	6.9	38
537	Antidepressants and mania: To stop or not to stop?. Human Psychopharmacology, 1993, 8, 357-360.	1.5	7
538	Saccadic eye movement parameters in normal subjects. Electroencephalography and Clinical Neurophysiology, 1993, 86, 69-74.	0.3	65
539	The Effects of Electroconvulsive Therapy on Plasma Insulin and Glucose in Depression. British Journal of Psychiatry, 1992, 161, 94-98.	2.8	10
540	Panic Attacks. British Journal of Psychiatry, 1992, 160, 165-178.	2.8	152

#	ARTICLE	IF	CITATIONS
541	Characterization and autoradiographical localization of non- α -adrenoceptor idazoxan binding sites in the rat brain. <i>British Journal of Pharmacology</i> , 1992, 106, 1019-1027.	5.4	115
542	Are 5-HT receptors or β -adrenoceptors involved in idazoxan-induced food and water intake?. <i>Neuropharmacology</i> , 1992, 31, 1081-1087.	4.1	9
543	Flumazenil and saccadic eye movements in patients with panic disorder and normal controls. <i>Human Psychopharmacology</i> , 1992, 7, 45-50.	1.5	7
544	Pharmacology of saccadic eye movements in man. <i>Psychopharmacology</i> , 1991, 105, 361-367.	3.1	83
545	The effects of the β -adrenoceptor antagonist idazoxan on sleep in normal volunteers. <i>Journal of Psychopharmacology</i> , 1991, 5, 105-110.	4.0	8
546	Acute and chronic idazoxan in normal volunteers: biochemical, physiological and psychological effects. <i>Journal of Psychopharmacology</i> , 1991, 5, 396-403.	4.0	17
547	Overexcitement and Disinhibition. <i>British Journal of Psychiatry</i> , 1990, 157, 491-499.	2.8	84
548	Flumazenil Provocation of Panic Attacks. <i>Archives of General Psychiatry</i> , 1990, 47, 917.	12.3	261
549	Altered Central β -Adrenoceptor Sensitivity in Panic Disorder. <i>Archives of General Psychiatry</i> , 1989, 46, 165.	12.3	147
550	Evidence that imipramine-induced postural hypotension may be centrally mediated. <i>Human Psychopharmacology</i> , 1988, 3, 181-190.	1.5	6
551	Strain differences in response to a benzodiazepine receptor inverse agonist (FG 7142) in mice. <i>Psychopharmacology</i> , 1988, 94, 335-6.	3.1	34
552	Panic attacks and alcohol withdrawal: Can subjects differentiate the symptoms?. <i>Biological Psychiatry</i> , 1988, 24, 240-243.	1.3	46
553	Neuroreceptor Science. <i>Journal of Clinical Psychopharmacology</i> , 1988, 8, 387-390.	1.4	2
554	The effects of chronic ritanserin treatment on sleep and the neuroendocrine response to l-tryptophan. <i>Psychopharmacology</i> , 1987, 93, 416-20.	3.1	72
555	L-Tryptophan and prolactin release: Evidence for interaction between 5-HT ₁ and 5-HT ₂ receptors. <i>Human Psychopharmacology</i> , 1986, 1, 93-97.	1.5	78
556	ABSTINENCE SYMPTOMS AFTER WITHDRAWAL OF TRANQUILLISING DRUGS: IS THERE A COMMON NEUROCHEMICAL MECHANISM?. <i>Lancet</i> , The, 1982, 320, 360-362.	13.7	83
557	The anxiogenic action of benzodiazepine antagonists. <i>Neuropharmacology</i> , 1982, 21, 1033-1037.	4.1	266
558	Unusual interactions of benzodiazepine receptor antagonists. <i>Nature</i> , 1982, 295, 436-438.	27.8	292

#	ARTICLE	IF	CITATIONS
559	Current Trends in Cognitive Behaviour Therapy for Anxiety Disorders. , 0, , 265-286.		0
560	Panic Disorder: Clinical Course, Morbidity and Comorbidity. , 0, , 51-79.		4
561	Generalised Anxiety Disorder. , 0, , 187-204.		3
562	Post-Traumatic Syndromes: Comparative Biology and Psychology. , 0, , 205-221.		0
563	Obsessive-Compulsive Disorder: Diagnostic Considerations and an Epidemiological Update. , 0, , 157-168.		0
564	Genetics of Anxiety Disorders: Part I. , 0, , 25-40.		0
565	Panic Disorder: Pathogenesis and Treatment. , 0, , 81-103.		1
566	The Experience Sampling Method in Stress and Anxiety Research. , 0, , 289-306.		4
567	Genetics of Anxiety Disorders: Part II. , 0, , 41-50.		0
568	A Case Study of the 35% CO2 Challenge. , 0, , 339-357.		9
569	Obsessive-Compulsive Disorder: Biology and Treatment, a Generation of Progress. , 0, , 169-186.		0
570	Clinical Testing of Anxiolytic Drugs. , 0, , 325-337.		1
571	The Pharmacology of Human Anxiety. , 0, , 309-324.		3
572	Learning Perspectives on Anxiety Disorders. , 0, , 245-264.		3
573	Specific Phobias. , 0, , 105-135.		0
574	Social Phobia. , 0, , 137-155.		0
575	Epidemiology of Anxiety Disorders. , 0, , 1-23.		1
576	Why doctors have a moral imperative to prescribe and support medical cannabisâ€”an essay by David Nutt. BMJ, The, 0, , n3114.	6.0	26

#	ARTICLE	IF	CITATIONS
577	The Psychobiology of Post-Traumatic Stress Disorder. , 0, , 223-244.		4
578	The Tryptophan Depletion Technique in Psychiatric Research. , 0, , 359-369.		1
579	Characteristics of People Seeking Prescribed Cannabinoids for the Treatment of Chronic Pain: Evidence From Project Twenty 21. Frontiers in Pain Research, 0, 3, .	2.0	9